跳至主要内容
临床试验/CTRI/2024/04/065955
CTRI/2024/04/065955尚未招募3 期

A Comparative study to evaluate the efficacy of Tofacitinib and Adalimumab in treating axial spondyloarthritis: An open label randomized controlled trial - NI

Institute of post graduate graduate medical education and research0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients fulfilling the ASAS classification criteria for axial SpA including both non radiographic axial spondyloarthritis (nr-AxSpA) and ankylosing spondylitis (AS)
  • Patients with BASDAI =4 or ASDAS-CRP=2.1.
  • Biologic DMARD (b DMARD) and targeted synthetic DMARD (ts DMARD) naïve patients who have undergone a trial of at least 2 courses of NSAIDs with optimum doses for at least 1 month without response or with partial response.
  • Patients with prior b DMARD and ts DMARD permitted if discontinued for =4 weeks or =5 half-lives (whichever was longer) before randomization.

排除标准

  • 未提供

研究者

发起方
Institute of post graduate graduate medical education and research

相似试验

A clinical study to compare the effect of two drugs,... | 临床试验